Illuminating the molecular events linking chronic hepatic injury, regeneration, fibrosis and cancer is among the most fundamental of challenges in investigative hepatology. Today's epidemic of end-stage liver disease due to hepatic fibrosis with a heightened risk of liver cancer has precipitated an urgent need for new therapies. Severe liver disease is characterized by the `ductular reaction', whereby hepatobiliary liver progenitor cells (LPCs) expand and fibrosis accumulates. We have identified an exciting and novel link between loss of autophagy in hepatocytes, a pathway that preserves energy homeostasis, and dysregulation of the Hippo tumor suppressor pathway, leading to massive expansion of LPCs, fibrosis and severe hepatomegaly. These findings indicate that autophagy and Hippo sit at the nexus of organ size control, LPC homeostasis, fibrosis and liver cancer. Our long-term goal is to understand the relationship between hepatocyte injury, liver progenitor cell (LPC) homeostasis and fibrosis to clarify how these processes contribute to acute and chronic liver disease. Our central hypothesis is that loss of autophagy in hepatocytes leads to cell autonomous suppression of Hippo signaling with stabilization of Yap (molecules that migrate to the nucleus to promote growth when Hippo signaling is disrupted), leading to hepatomegaly and tumorigenesis. Non-cell autonomous effects from loss of autophagy in hepatocytes provoke expansion of LPCs, which communicate with hepatic stellate cells (HSCs) to generate fibrosis and promote cancer. The following Specific Aims will test this hypothesis: 1. To clarify mechanism(s) linking autophagy loss to Hippo blockade and Yap accumulation, by systematically analyzing Hippo components in livers with hepatocyte autophagy loss, testing whether the phenotype is rescued by blocking Yap genetically or chemically, and uncovering the mechanism linking autophagy loss to Yap accumulation. 2. To identify key factors generated by autophagy-deficient hepatocytes that induce LPC expansion by quantifying LPC expansion in vivo, identifying secreted factors from autophagy- deficient hepatocytes (esp. CTGF) that drive this expansion, and functionally testing candidate mediators by inhibiting their expression using either neutralizing antibodies or siRNAs. 3. To define the crosstalk between fibrogenic LPCs and HSCs using a collagen I reporter mouse to quantify relative fibrogenic contributions, define specific bi-directional fibrogenic pathways driven by CTGF or other mediators between LPCs and HSCs in culture and in vivo, and correlate transcriptomic expression profiles of these fibrogenic cells with profiles in human liver disease with or without ductular reaction using gene set enrichment analysis. These studies will uncover novel pathways of cell proliferation and the response to injury in hepatocytes, and fibrogenesis by LPCs and HSCs. Opportunities for manipulation of pathways involved in fibrogenesis will emerge, leading to novel anti-fibrotic, regenerative and/or anti-tumorigenic treatments.

Public Health Relevance

Chronic liver disease leads to scarring, or fibrosis of the liver, and is a major public health threat, affecting hundreds of millions of individuals worldwide. We propose to understand how damage to the liver leads to either regeneration or scarring. New insights expected to emerge from these novel studies could significantly advance our understanding of how to block scar formation and enhance regeneration in chronic liver disease, accelerate liver repair, and prevent the end-stage of liver disease called cirrhosis, thereby improving the lives of patients throughout the developed and developing world.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK056621-18
Application #
9750062
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Burgess-Beusse, Bonnie L
Project Start
2000-05-01
Project End
2020-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
18
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Zeng, Zhiping; Wu, Yujing; Cao, Yirong et al. (2018) Slit2-Robo2 signaling modulates the fibrogenic activity and migration of hepatic stellate cells. Life Sci 203:39-47
Tsuchida, Takuma; Lee, Youngmin A; Fujiwara, Naoto et al. (2018) A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 69:385-395
Lee, Youngmin A; Noon, Luke A; Akat, Kemal M et al. (2018) Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nat Commun 9:4962
de Oliveira da Silva, Brenda; Alberici, Luciane Carla; Ramos, Letícia Ferreira et al. (2018) Altered global microRNA expression in hepatic stellate cells LX-2 by angiotensin-(1-7) and miRNA-1914-5p identification as regulator of pro-fibrogenic elements and lipid metabolism. Int J Biochem Cell Biol 98:137-155
Shalom-Barak, Tali; Liersemann, Jaclyn; Memari, Babak et al. (2018) Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor ?-Retinoid X Receptor ? Coactivator. Mol Cell Biol 38:
Bansal, Ruchi; Nakagawa, Shigeki; Yazdani, Saleh et al. (2017) Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. Exp Mol Med 49:e396
Wooden, Benjamin; Goossens, Nicolas; Hoshida, Yujin et al. (2017) Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology 152:53-67.e3
Hicks, Daniel F; Goossens, Nicolas; Blas-García, Ana et al. (2017) Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Sci Rep 7:42563
Narayan, Prakash; Duan, Bin; Jiang, Kai et al. (2016) Late intervention with the small molecule BB3 mitigates postischemic kidney injury. Am J Physiol Renal Physiol 311:F352-61
Gallardo-Vara, Eunate; Blanco, Francisco J; Roqué, Mercè et al. (2016) Transcription factor KLF6 upregulates expression of metalloprotease MMP14 and subsequent release of soluble endoglin during vascular injury. Angiogenesis 19:155-71

Showing the most recent 10 out of 139 publications